文献速递衰弱、肌少症与跌倒老年慢病共病管理

性别是促长寿药物疗效的主要决定因素:NIA干预测试计划二十年综述

Sex as a major determinant of pro-longevity drug efficacy: a review of two decades of the NIA Interventions Testing Program.
PubMed 文献 · J Gerontol A Biol Sci Med Sci · 2025-01-01

Aging is the primary risk factor for frailty, sarcopenia, and functional decline, as well as cancer, cardiovascular and neurodegenerative diseases.…

要点

  • 多数延长寿命的化合物主要或仅对雄性小鼠有效。
  • 剂量和治疗起始年龄影响疗效,且呈性别二态性。
  • 生物学性别应被视为治疗效果的修饰因素。

核心结论

  • 衰老机制具有性别二态性,生物学性别是促长寿干预疗效的重要修饰因素。

研究设计与样本

  • 美国国家老龄化研究所于2004年启动多站点干预测试计划(ITP),使用遗传异质性UM-HET3小鼠评估候选化合物。

主要发现

  • 多数延长寿命的化合物主要或仅对雄性小鼠有效。
  • 剂量和治疗起始年龄影响疗效,且这些影响也呈性别二态性。

临床怎么用

  • 在开发老年保护策略时,应认识到生物学性别对治疗效果的修饰作用,并探索性别差异的基础以制定更有针对性的干预措施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Aging is the primary risk factor for frailty, sarcopenia, and functional decline, as well as cancer, cardiovascular and neurodegenerative diseases. Gaining insight into the biological mechanisms of aging could lead to interventions that broadly reduce age-related morbidity and mortality. To identify interventions that extend lifespan and delay aging, the National Institute on Aging launched the Interventions Testing Program (ITP) in 2004. This multi-site effort uses genetically heterogeneous UM-HET3 mice to evaluate the effects of candidate compounds. Over the past two decades, the ITP has tested 54 agents in more than 30, 000 mice. This is the first comprehensive review of the program's results, with particular emphasis on a striking pattern of sex-specific responses. By presenting the full scope of the findings, readers can better understand the overall impact of the program and easily access detailed information on specific drugs of interest. Notably, most compounds that extended lifespan were effective primarily or exclusively in male mice. Dosage and age of treatment onset influenced efficacy and were also sexually dimorphic. These sex differences suggest that mechanisms of aging are sexually dimorphic and highlight the importance of recognizing biological sex as a modifier of treatment efficacy. Investigating the basis for these differences should enable more targeted and effective geroprotective strategies for both sexes.

来源:J Gerontol A Biol Sci Med Sci,查看原文。版权归原作者所有。

引用

  1. Jiang N, Xu Z, Zhao S, et al. Sex as a major determinant of pro-longevity drug efficacy: a review of two decades of the NIA Interventions Testing Program. J Gerontol A Biol Sci Med Sci. 2025. PMID: 40717358. doi:10.1093/gerona/glaf138

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。